HY-116096 Search Results


prdx2 inhibitor conoidin a  (MedChemExpress)
93
MedChemExpress prdx2 inhibitor conoidin a
<t>PRDX2</t> Expression and Analysis in Sequencing of TNBC Clinical Samples and Tissues. ( A ) Flowchart illustrating the PRDX2 staining process in tissues from TNBC patients. The right panel shows the distribution map of tumor ( n = 150) and adjacent tissues ( n = 30). ( B ) Immunohistochemical analysis of PRDX2 expression in TNBC tissues. The right panel provides a high-magnification view of the area within the black dashed box; the red dashed box highlights tumor cells with high PRDX2 expression. Scale bars = 20 μm. ( C ) Statistical bar chart depicting PRDX2 expression levels in tumor and paracancerous tissues of TNBC patients. ( D ) Differentially expressed genes between tumor and adjacent tissues of TNBC (ER-, PR-, and HER2-) patients, as identified in the TCGA database. Screening criteria:|log2FC| > 1 and P < 0.05. Red indicates high expression, and blue indicates low expression. ( E ) Venn diagram showing the intersection of upregulated genes and migration/invasion-related genes in tumors of TNBC patients. ( F ) Heatmap illustrating the correlation between PRDX2 and migration/invasion-related genes in tumor tissues of TNBC patients, based on data from the TCGA database. Red represents positive correlation, and blue represents negative correlation. Data are presented as mean ± standard error (mean ± SEM). P values and significance were determined using two-tailed unpaired t-tests ( C ). * P ≤ 0.05; ** P ≤ 0.01
Prdx2 Inhibitor Conoidin A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prdx2 inhibitor conoidin a/product/MedChemExpress
Average 93 stars, based on 1 article reviews
prdx2 inhibitor conoidin a - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


PRDX2 Expression and Analysis in Sequencing of TNBC Clinical Samples and Tissues. ( A ) Flowchart illustrating the PRDX2 staining process in tissues from TNBC patients. The right panel shows the distribution map of tumor ( n = 150) and adjacent tissues ( n = 30). ( B ) Immunohistochemical analysis of PRDX2 expression in TNBC tissues. The right panel provides a high-magnification view of the area within the black dashed box; the red dashed box highlights tumor cells with high PRDX2 expression. Scale bars = 20 μm. ( C ) Statistical bar chart depicting PRDX2 expression levels in tumor and paracancerous tissues of TNBC patients. ( D ) Differentially expressed genes between tumor and adjacent tissues of TNBC (ER-, PR-, and HER2-) patients, as identified in the TCGA database. Screening criteria:|log2FC| > 1 and P < 0.05. Red indicates high expression, and blue indicates low expression. ( E ) Venn diagram showing the intersection of upregulated genes and migration/invasion-related genes in tumors of TNBC patients. ( F ) Heatmap illustrating the correlation between PRDX2 and migration/invasion-related genes in tumor tissues of TNBC patients, based on data from the TCGA database. Red represents positive correlation, and blue represents negative correlation. Data are presented as mean ± standard error (mean ± SEM). P values and significance were determined using two-tailed unpaired t-tests ( C ). * P ≤ 0.05; ** P ≤ 0.01

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: PRDX2 Expression and Analysis in Sequencing of TNBC Clinical Samples and Tissues. ( A ) Flowchart illustrating the PRDX2 staining process in tissues from TNBC patients. The right panel shows the distribution map of tumor ( n = 150) and adjacent tissues ( n = 30). ( B ) Immunohistochemical analysis of PRDX2 expression in TNBC tissues. The right panel provides a high-magnification view of the area within the black dashed box; the red dashed box highlights tumor cells with high PRDX2 expression. Scale bars = 20 μm. ( C ) Statistical bar chart depicting PRDX2 expression levels in tumor and paracancerous tissues of TNBC patients. ( D ) Differentially expressed genes between tumor and adjacent tissues of TNBC (ER-, PR-, and HER2-) patients, as identified in the TCGA database. Screening criteria:|log2FC| > 1 and P < 0.05. Red indicates high expression, and blue indicates low expression. ( E ) Venn diagram showing the intersection of upregulated genes and migration/invasion-related genes in tumors of TNBC patients. ( F ) Heatmap illustrating the correlation between PRDX2 and migration/invasion-related genes in tumor tissues of TNBC patients, based on data from the TCGA database. Red represents positive correlation, and blue represents negative correlation. Data are presented as mean ± standard error (mean ± SEM). P values and significance were determined using two-tailed unpaired t-tests ( C ). * P ≤ 0.05; ** P ≤ 0.01

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Expressing, Sequencing, Staining, Immunohistochemical staining, Migration, Two Tailed Test

PRDX2 Promotes Migration and Invasion of Breast Cancer Cells. ( A ) Workflow for lentivirus preparation and transfection of breast cancer cells. The right shows the BF and fluorescence images of MDA-MB-231 and MDA-MB-468 cells. Scale bars = 200 μm. ( B ) Detection of PRDX2 gene and protein expression in breast cancer cells. ( C , D ) Analysis of gene and protein expression related to migration, invasion, and epithelial-mesenchymal transition (EMT) in MDA-MB-231 ( C ) and MDA-MB-468 ( D )breast cancer cells. migration Scale bars = 100 μm; invasion Scale bars = 50 μm. ( E ) Transcriptome sequencing of MDA-MB-231 cells transfected with sh_NC or sh_PRDX2. ( F ) GO and KEGG enrichment analysis of differentially expressed genes inMDA-MB-231 cells. ( G ) Venn diagram showing the intersection of differentially expressed genes and genes associated with invasion and metastasis. Data are presented as mean ± standard error of the mean (mean ± SEM). P values and Statistical significance was determined using two-tailed unpaired t-tests ( C , D ) and one-way ANOVA ( B ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: PRDX2 Promotes Migration and Invasion of Breast Cancer Cells. ( A ) Workflow for lentivirus preparation and transfection of breast cancer cells. The right shows the BF and fluorescence images of MDA-MB-231 and MDA-MB-468 cells. Scale bars = 200 μm. ( B ) Detection of PRDX2 gene and protein expression in breast cancer cells. ( C , D ) Analysis of gene and protein expression related to migration, invasion, and epithelial-mesenchymal transition (EMT) in MDA-MB-231 ( C ) and MDA-MB-468 ( D )breast cancer cells. migration Scale bars = 100 μm; invasion Scale bars = 50 μm. ( E ) Transcriptome sequencing of MDA-MB-231 cells transfected with sh_NC or sh_PRDX2. ( F ) GO and KEGG enrichment analysis of differentially expressed genes inMDA-MB-231 cells. ( G ) Venn diagram showing the intersection of differentially expressed genes and genes associated with invasion and metastasis. Data are presented as mean ± standard error of the mean (mean ± SEM). P values and Statistical significance was determined using two-tailed unpaired t-tests ( C , D ) and one-way ANOVA ( B ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Migration, Transfection, Fluorescence, Expressing, Sequencing, Two Tailed Test

PRDX2 Regulates FN1 to Promote Migration and EMT of Breast Cancer Cells. ( A-B ) mRNA (Bar chart) and protein expression levels of PRDX2, FN1, COL6A2, and ITGB3 in breast cancer cell lines MDA-MB-231 ( A ) and MDA-MB-468 ( B ) under conditions of PRDX2 knockdown (sh_PRDX2) compared to negative control (sh_NC). ( C-E ) The effects of FN1 ( C ), COL6A2 ( D ), and ITGB3 ( E ) knockdown on the migratory capacity of PRDX2-knockdown breast cancer cells (MDA-MB-231), with scale bars = 200 μm. F. The impact of FN1, COL6A2, and ITGB3 knockdown on the expression of EMT markers (E-cadherin, N-cadherin, VIM) and matrix metalloproteinases (MMP3, MMP9) in PRDX2-knockdown breast cancer cells (MDA-MB-231). Data are represented as mean ± standard error of the mean (mean ± SEM). P values and statistical significance was assessed using two-tailed unpaired t-tests ( A-B ). ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: PRDX2 Regulates FN1 to Promote Migration and EMT of Breast Cancer Cells. ( A-B ) mRNA (Bar chart) and protein expression levels of PRDX2, FN1, COL6A2, and ITGB3 in breast cancer cell lines MDA-MB-231 ( A ) and MDA-MB-468 ( B ) under conditions of PRDX2 knockdown (sh_PRDX2) compared to negative control (sh_NC). ( C-E ) The effects of FN1 ( C ), COL6A2 ( D ), and ITGB3 ( E ) knockdown on the migratory capacity of PRDX2-knockdown breast cancer cells (MDA-MB-231), with scale bars = 200 μm. F. The impact of FN1, COL6A2, and ITGB3 knockdown on the expression of EMT markers (E-cadherin, N-cadherin, VIM) and matrix metalloproteinases (MMP3, MMP9) in PRDX2-knockdown breast cancer cells (MDA-MB-231). Data are represented as mean ± standard error of the mean (mean ± SEM). P values and statistical significance was assessed using two-tailed unpaired t-tests ( A-B ). ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Migration, Expressing, Knockdown, Negative Control, Two Tailed Test

Effects of PRDX2 Inhibition on a Mouse Model of Breast Cancer. ( A ) mouse model of breast cancer with PRDX2 inhibition was established, comprising four groups containing eight mice. ( B ) Subcutaneous tumor diagrams of the four groups of mice, with the dotted box indicating the tumor location. ( C ) Statistical plots of subcutaneous tumor volumes for the four groups of mice, with the dashed box highlighting the tumor size. Scale bars = 1 cm. ( D ) Immunofluorescence (IF) analysis was performed to assess the protein expression levels of PRDX2 (indicated by the yellow dotted box) and FN1 (indicated by the white dotted box) in the tumor tissues of the four groups of mice. Scale bars = 20 μm. ( E , F ) Immunohistochemical (IHC) staining was conducted to evaluate the protein expression of MMP3 ( E )and E-cadherin ( F ) in the tumor tissues; black arrows denote the locations of positive cell expression. Scalebars = 20 μm. Data are presented as mean ± standard error (mean ± SEM). P values and statistical significance was determined using two-tailed unpaired t-tests ( C ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: Effects of PRDX2 Inhibition on a Mouse Model of Breast Cancer. ( A ) mouse model of breast cancer with PRDX2 inhibition was established, comprising four groups containing eight mice. ( B ) Subcutaneous tumor diagrams of the four groups of mice, with the dotted box indicating the tumor location. ( C ) Statistical plots of subcutaneous tumor volumes for the four groups of mice, with the dashed box highlighting the tumor size. Scale bars = 1 cm. ( D ) Immunofluorescence (IF) analysis was performed to assess the protein expression levels of PRDX2 (indicated by the yellow dotted box) and FN1 (indicated by the white dotted box) in the tumor tissues of the four groups of mice. Scale bars = 20 μm. ( E , F ) Immunohistochemical (IHC) staining was conducted to evaluate the protein expression of MMP3 ( E )and E-cadherin ( F ) in the tumor tissues; black arrows denote the locations of positive cell expression. Scalebars = 20 μm. Data are presented as mean ± standard error (mean ± SEM). P values and statistical significance was determined using two-tailed unpaired t-tests ( C ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Inhibition, Immunofluorescence, Expressing, Immunohistochemical staining, Immunohistochemistry, Two Tailed Test

PRDX2 Promotes SP1 Binding to the FN1 Promoter via the PI3K/AKT/SP1 Signaling Pathway. ( A ) Screening and Analysis of Core Transcription Factors Regulating Migration and Invasion Genes. ( B , C ) Protein Expression Levels of PRDX2 and Core Transcription Factors (c-Jun, p-SP1, p-p65) in Breast Cancer Cells MDA-MB-231 ( B ) and MDA-MB-468 ( C ) under SH_NC/PRDX2 Conditions. ( D ) Top Three Differentially Expressed Genes in MDA-MB-231 Cells Identified by KEGG Enrichment Analysis. ( E , F ) Protein Expression Levels of PRDX2 and Key Kinases (p-PI3K, p-AKT) as well as Transcription Factor (p-SP1) in Breast Cancer Cells MDA-MB-231 ( E ) and MDA-MB-468 ( F ) under NC/sh_PRDX2 Conditions. ( G ) SP1 Binds to Three Potential Sites in the FN1 Promoter. ( H ) SP1 Protein Expression Levels Following Transfection with Wild-Type and h-SP1 Overexpression Plasmids in HEK-293 Cells( I ) After transfecting wild-type/h-SP1 overexpression plasmids into HEK-293T cells expressing the WT/mutant FN1 promoter, luciferase activity was detected. ( J ) Immunofluorescence (IF) detection of the expression levels of PRDX2 and SP1 proteins in tumor tissues from four groups of mice, Scale bars = 20 μm.Data are presented as mean ± standard error (mean ± SEM). P values and statistical significance was determined using two-tailed unpaired t-tests ( H ) and One-Way ANOVA ( I ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: PRDX2 Promotes SP1 Binding to the FN1 Promoter via the PI3K/AKT/SP1 Signaling Pathway. ( A ) Screening and Analysis of Core Transcription Factors Regulating Migration and Invasion Genes. ( B , C ) Protein Expression Levels of PRDX2 and Core Transcription Factors (c-Jun, p-SP1, p-p65) in Breast Cancer Cells MDA-MB-231 ( B ) and MDA-MB-468 ( C ) under SH_NC/PRDX2 Conditions. ( D ) Top Three Differentially Expressed Genes in MDA-MB-231 Cells Identified by KEGG Enrichment Analysis. ( E , F ) Protein Expression Levels of PRDX2 and Key Kinases (p-PI3K, p-AKT) as well as Transcription Factor (p-SP1) in Breast Cancer Cells MDA-MB-231 ( E ) and MDA-MB-468 ( F ) under NC/sh_PRDX2 Conditions. ( G ) SP1 Binds to Three Potential Sites in the FN1 Promoter. ( H ) SP1 Protein Expression Levels Following Transfection with Wild-Type and h-SP1 Overexpression Plasmids in HEK-293 Cells( I ) After transfecting wild-type/h-SP1 overexpression plasmids into HEK-293T cells expressing the WT/mutant FN1 promoter, luciferase activity was detected. ( J ) Immunofluorescence (IF) detection of the expression levels of PRDX2 and SP1 proteins in tumor tissues from four groups of mice, Scale bars = 20 μm.Data are presented as mean ± standard error (mean ± SEM). P values and statistical significance was determined using two-tailed unpaired t-tests ( H ) and One-Way ANOVA ( I ). * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Binding Assay, Migration, Expressing, Transfection, Over Expression, Mutagenesis, Luciferase, Activity Assay, Immunofluorescence, Two Tailed Test

PRDX2 plays a pivotal role in breast cancer invasion and metastasis by activating the PI3K/AKT signaling pathway, subsequently promoting the binding of SP1 to the FN1 promoter

Journal: Journal of Translational Medicine

Article Title: Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway

doi: 10.1186/s12967-025-06441-2

Figure Lengend Snippet: PRDX2 plays a pivotal role in breast cancer invasion and metastasis by activating the PI3K/AKT signaling pathway, subsequently promoting the binding of SP1 to the FN1 promoter

Article Snippet: The PRDX2 inhibitor Conoidin A was synthesized by MCE (#HY-116090), and a stock solution was prepared using DMSO (Sigma, #D4540-100 ml).

Techniques: Binding Assay